ClinicalTrials.gg
CompletedNCT02227212Updated Dec 3, 2014

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

A Phase 3 interventional study of Insulin glargine U300 (new formulation of insulin glargine) HOE901 in Diabetes Mellitus Type 2, sponsored by Sanofi. Completed at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-03.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
155th of 178
40 · median 334
Started
2014
with 5 others
Phase 3
80 of 186
none open now
Registered
124th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 155th largest by enrollment of the 178 interventional ones that give a count, is one of 6 that started in 2014, is one of 80 in phase 3, and was the 124th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the ease of use of the U300 pen injector in pen-naïve and insulin-naïve type 2 diabetes mellitus (T2DM) patients in a 4-week once-daily dosing regimen with HOE901-U300.

Secondary Objectives:

To assess in a 4-week once-daily dosing regimen with HOE901-U300 in pen-naïve and insulin-naïve T2DM patients.

The safety and usability of the U300 pen injector. The glycemic control with the U300 pen injector. The safety of HOE901-U300.

Read the detailed description

The total study duration for a participants can be approximately up to 10 weeks.

03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with T2DM inadequately controlled with non-insulin, non-injectable anti-hyperglycemic drug(s) and for whom the Investigator/treating physicians has decided that basal insulin is appropriate.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • A1c (HbA1c) \<7.0% (\<53 mmol/mol) or >11% (97 mmol/mol) at screening.
  • Age \<18 years at the time of screening.
  • (BMI) >40 kg/m2.
  • Diabetes other than T2DM.
  • History of T2DM for less than 1 year before screening.
  • Less than 6 months anti-hyperglycemic treatment before screening.
  • Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit.
  • Previous treatment with Glucagon Like Peptide-1 (GLP-1) agonist.
  • Patients receiving only non-insulin anti-hyperglycemic drugs not approved for combination with insulin according to local labeling/local treatment guidelines and/or sulfonylurea or glinides.
  • Current or previous insulin use except for a maximum of 8 consecutive days and a total of 14 days (eg, acute illness, surgery) during the last year prior to screening.
  • Any to insulin glargine (Lantus) according to the National Product labeling or any .
  • Any contraindication to the mandatory background non-insulin anti-hyperglycemic medication according to the respective National Product labeling.
  • Latest eye examination by an ophthalmologist >12 months prior to inclusion.
  • More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months.
  • Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Insulin glargine U300

    Once daily subcutaneous injection for 4 weeks

    Drug: Insulin glargine U300 (new formulation of insulin glargine) HOE901

Interventions

  • DrugInsulin glargine U300 (new formulation of insulin glargine) HOE901

    Pharmaceutical form:solution for injection Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Ease-of-use / ease of learning questionnaire

    Time frame: Day 1, Day 7 , 4-weeks

Secondary outcomes

  1. Change in treatment satisfaction score (sum of items 1, 4, 5, 6, 7, and 8 from Diabetes Treatment Satisfaction Questionnaire [status]) from baseline to Week 4

    Time frame: Baseline, week 4

  2. Change in perception of hyper- and hypoglycemia score (items 2 and 3 from Diabetes Treatment Satisfaction Questionnaire [status]) from baseline to Week 4

    Time frame: Baseline, week 4

  3. Change in fasting plasma glucose (FPG) (mmol/L) from baseline to Week 4

    Time frame: Baseline, week 4

  4. Number of participants with Product Technical Complaints (PTC)

    Time frame: Baseline to week 4

  5. Number of participants with adverse events and hypoglycemic events related to PTC

    Time frame: Baseline to week 4

  6. Change in daily insulin dose (U and U/kg) from Day 1 to Week 4 (patient diary)

    Time frame: Baseline, week 4

  7. Number of participants with adverse events

    Time frame: screening to week 6

  8. Incidence and frequency of hypoglycemia episodes. Hypoglycemia will be analyzed by hypoglycemia categories as defined by American Diabetes Association

    Time frame: screening to week 6

  9. Potentially clinically significant changes in laboratory evaluations, vital signs, electrocardiogram (ECG)

    Time frame: screening, baseline, week 4

  10. Number of participants with site injection site reactions / hypersensitivity reactions

    Time frame: baseline to week 6

07

Study locations

7 sites
  • Investigational Site Number 276011
    Augsburg, 86150, Germany
  • Investigational Site Number 276008
    Berlin, 10115, Germany
  • Investigational Site Number 276009
    Essen, 45355, Germany
  • Investigational Site Number 276002
    Hamburg, 22607, Germany
  • Investigational Site Number 276001
    Münster, 48145, Germany
  • Investigational Site Number 276007
    Potsdam, 14469, Germany
  • Investigational Site Number 276004
    Wangen, 88239, Germany
08

References and documents

Publications

  • Pohlmeier H, Berard L, Brulle-Wohlhueter C, Wu J, Dahmen R, Nowotny I, Klonoff D. Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naive People With Type 2 Diabetes. J Diabetes Sci Technol. 2017 Mar;11(2):263-269. doi: 10.1177/1932296816668877. Epub 2016 Sep 25. PubMed 27664062 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2014
First posted
Aug 28, 2014
Start
Aug 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Dec 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02227212
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 28, 2014
Start date
Aug 2014
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Dec 3, 2014

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion